Anesthetic and Analgesic Drug Products Advisory Committee

Anesthetic and Analgesic Drug Products Advisory Committee Committee Meeting July 18, 2013, from 8 a.m. to 5 p.m. (Day 2 of 2) Agenda: On July 18, 2013, the committee will discuss new drug application (NDA) 022225, sugammadex sodium injection, submitted by Organon USA Inc., for the proposed indications of routine reversal of moderate and deep neuromuscular blockade (NMB) induced by rocuronium or vecuronium and immediate reversal of NMB at 3 minutes after administration of rocuronium.